$2.37 Billion is the total value of Artal Group S.A.'s 105 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 76.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| XLRN | Buy | ACCELERON PHARMA INC | $134,805,000 | +111.9% | 1,500,000 | +25.0% | 5.70% | +131.8% |
| ALNY | Buy | ALNYLAM PHARMACEUTICALS INC | $119,735,000 | +4.0% | 1,100,000 | +10.0% | 5.06% | +13.7% |
| BGNE | Buy | BEIGENE LTDsponsored adr | $80,022,000 | -24.6% | 650,000 | +1.6% | 3.38% | -17.5% |
| BABA | New | ALIBABA GROUP HLDG LTDcall | $77,792,000 | – | 400,000 | +100.0% | 3.29% | – |
| ARGX | Buy | ARGENX SEsponsored adr | $62,572,000 | +11.4% | 475,000 | +35.7% | 2.64% | +21.8% |
| QURE | New | UNIQURE NV | $54,568,000 | – | 1,150,000 | +100.0% | 2.31% | – |
| FATE | Buy | FATE THERAPEUTICS INC | $46,641,000 | +19.2% | 2,100,000 | +5.0% | 1.97% | +30.4% |
| FOLD | Buy | AMICUS THERAPEUTICS INC | $46,200,000 | +58.1% | 5,000,000 | +66.7% | 1.95% | +72.9% |
| BAC | New | BK OF AMERICA CORPcall | $42,460,000 | – | 2,000,000 | +100.0% | 1.79% | – |
| BDTX | New | BLACK DIAMOND THERAPEUTICS I | $42,328,000 | – | 1,696,517 | +100.0% | 1.79% | – |
| PYPL | Buy | PAYPAL HLDGS INC | $42,126,000 | +94.7% | 440,000 | +120.0% | 1.78% | +112.9% |
| XBI | New | SPDR SER TRcall | $38,720,000 | – | 500,000 | +100.0% | 1.64% | – |
| SDGR | New | SCHRODINGER INC | $38,698,000 | – | 897,445 | +100.0% | 1.64% | – |
| EPZM | Buy | EPIZYME INC | $35,673,000 | -35.6% | 2,300,000 | +2.2% | 1.51% | -29.5% |
| XLI | New | SELECT SECTOR SPDR TRcall | $35,406,000 | – | 600,000 | +100.0% | 1.50% | – |
| DCPH | Buy | DECIPHERA PHARMACEUTICALS IN | $32,936,000 | +111.7% | 800,000 | +220.0% | 1.39% | +131.6% |
| Z | Buy | ZILLOW GROUP INCcl c cap stk | $32,418,000 | -5.9% | 900,000 | +20.0% | 1.37% | +2.9% |
| MA | New | MASTERCARD INCcall | $24,156,000 | – | 100,000 | +100.0% | 1.02% | – |
| IOVA | Buy | IOVANCE BIOTHERAPEUTICS INC | $22,451,000 | +62.2% | 750,000 | +50.0% | 0.95% | +77.4% |
| ATRA | Buy | ATARA BIOTHERAPEUTICS INC | $21,275,000 | -26.2% | 2,500,000 | +42.9% | 0.90% | -19.3% |
| FGEN | Buy | FIBROGEN INC | $20,850,000 | +21.5% | 600,000 | +50.0% | 0.88% | +32.9% |
| GOSS | Buy | GOSSAMER BIO INC | $18,361,000 | -27.0% | 1,808,968 | +12.4% | 0.78% | -20.2% |
| RUBY | Buy | RUBIUS THERAPEUTICS INC | $17,283,000 | -35.8% | 3,883,791 | +37.1% | 0.73% | -29.8% |
| ARWR | New | ARROWHEAD PHARMACEUTICALS IN | $17,262,000 | – | 600,000 | +100.0% | 0.73% | – |
| BMRN | Buy | BIOMARIN PHARMACEUTICAL INCcall | $16,900,000 | +99.9% | 200,000 | +100.0% | 0.71% | +118.3% |
| BBIO | Buy | BRIDGEBIO PHARMA INC | $15,950,000 | +127.5% | 550,000 | +175.0% | 0.67% | +148.7% |
| PRNB | New | PRINCIPIA BIOPHARMA INC | $14,845,000 | – | 250,000 | +100.0% | 0.63% | – |
| HARP | Buy | HARPOON THERAPEUTICS INC | $13,896,000 | +10.5% | 1,200,000 | +41.2% | 0.59% | +20.8% |
| VNET | New | 21VIANET GROUP INCsponsored ads | $13,860,000 | – | 1,000,000 | +100.0% | 0.59% | – |
| BPMC | Buy | BLUEPRINT MEDICINES CORPcall | $11,696,000 | +46.0% | 200,000 | +100.0% | 0.49% | +59.9% |
| TCOM | New | TRIP COM GROUP LTDads | $10,904,000 | – | 465,000 | +100.0% | 0.46% | – |
| AUPH | New | AURINIA PHARMACEUTICALS INC | $10,883,000 | – | 750,000 | +100.0% | 0.46% | – |
| SAGE | Buy | SAGE THERAPEUTICS INC | $10,052,000 | -7.2% | 350,000 | +133.3% | 0.42% | +1.7% |
| TGTX | Buy | TG THERAPEUTICS INC | $9,840,000 | +36.4% | 1,000,000 | +53.8% | 0.42% | +49.1% |
| ALBO | Buy | ALBIREO PHARMA INC | $9,628,000 | -15.9% | 588,125 | +30.6% | 0.41% | -7.9% |
| FOLD | Buy | AMICUS THERAPEUTICS INCcall | $9,240,000 | +89.7% | 1,000,000 | +100.0% | 0.39% | +107.4% |
| DNLI | Buy | DENALI THERAPEUTICS INC | $8,755,000 | +25.6% | 500,000 | +25.0% | 0.37% | +37.5% |
| ARAV | Buy | ARAVIVE INC | $8,352,000 | -54.7% | 1,450,000 | +7.4% | 0.35% | -50.5% |
| RGNX | Buy | REGENXBIO INC | $8,095,000 | +36.3% | 250,000 | +72.4% | 0.34% | +48.7% |
| MLCO | New | MELCO RESORTS AND ENTMNT LTDcall | $6,200,000 | – | 500,000 | +100.0% | 0.26% | – |
| ALEC | Buy | ALECTOR INC | $6,033,000 | +55.6% | 250,000 | +11.1% | 0.26% | +70.0% |
| ADVM | New | ADVERUM BIOTECHNOLOGIES INC | $5,862,000 | – | 600,000 | +100.0% | 0.25% | – |
| STOK | New | STOKE THERAPEUTICS INC | $5,725,000 | – | 250,000 | +100.0% | 0.24% | – |
| ADPT | Buy | ADAPTIVE BIOTECHNOLOGIES COR | $5,556,000 | +23.8% | 200,000 | +33.3% | 0.24% | +35.8% |
| CYCN | Buy | CYCLERION THERAPEUTICS INC | $4,933,000 | +33.2% | 1,861,584 | +36.7% | 0.21% | +45.5% |
| SPRO | Buy | SPERO THERAPEUTICS INC | $4,654,000 | -3.2% | 576,000 | +15.2% | 0.20% | +5.9% |
| IMAB | New | I MABsponsored ads | $4,550,000 | – | 350,000 | +100.0% | 0.19% | – |
| KRYS | Buy | KRYSTAL BIOTECH INC | $4,324,000 | -2.4% | 100,000 | +25.0% | 0.18% | +7.0% |
| New | TRILLIUM THERAPEUTICS INC | $4,040,000 | – | 1,000,000 | +100.0% | 0.17% | – | |
| PASG | New | PASSAGE BIO INC | $3,938,000 | – | 250,000 | +100.0% | 0.17% | – |
| EPZM | New | EPIZYME INCcall | $3,878,000 | – | 250,000 | +100.0% | 0.16% | – |
| APTX | New | APTINYX INC | $3,600,000 | – | 1,666,666 | +100.0% | 0.15% | – |
| ORTX | Buy | ORCHARD THERAPEUTICS PLCads | $3,012,000 | -37.4% | 400,000 | +14.3% | 0.13% | -31.7% |
| SYRS | New | SYROS PHARMACEUTICALS INC | $3,001,000 | – | 506,138 | +100.0% | 0.13% | – |
| PRVL | New | PREVAIL THERAPEUTICS INC | $2,438,000 | – | 200,000 | +100.0% | 0.10% | – |
| AXLA | Buy | AXCELLA HEALTH INC | $2,052,000 | +13.7% | 600,000 | +33.3% | 0.09% | +24.3% |
| AGLE | Buy | AEGLEA BIOTHERAPEUTICS INC | $1,864,000 | -18.7% | 400,000 | +33.3% | 0.08% | -11.2% |
| PTLA | New | PORTOLA PHARMACEUTICALS INC | $1,426,000 | – | 200,000 | +100.0% | 0.06% | – |
| RIGL | New | RIGEL PHARMACEUTICALS INC | $546,000 | – | 350,000 | +100.0% | 0.02% | – |
| LPTX | New | LEAP THERAPEUTICS INC | $395,000 | – | 250,000 | +100.0% | 0.02% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AGENUS INC | 42 | Q3 2023 | 1.9% |
| IRONWOOD PHARMACEUTICALS INC | 42 | Q3 2023 | 0.3% |
| ALNYLAM PHARMACEUTICALS INC | 37 | Q3 2023 | 5.1% |
| LEXICON PHARMACEUTICALS INC | 34 | Q3 2023 | 20.6% |
| AMICUS THERAPEUTICS INC | 30 | Q3 2023 | 2.7% |
| BEIGENE LTD | 28 | Q3 2023 | 7.4% |
| BK OF AMERICA CORP | 28 | Q1 2021 | 4.3% |
| SAGE THERAPEUTICS INC | 28 | Q2 2023 | 1.9% |
| AGIOS PHARMACEUTICALS INC | 28 | Q2 2020 | 1.1% |
| NEKTAR THERAPEUTICS | 27 | Q2 2020 | 1.3% |
View Artal Group S.A.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| WEIGHT WATCHERS INTERNATIONAL INC | February 13, 2015 | 29,443,300 | 51.9% |
View Artal Group S.A.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-05-17 |
| 4 | 2024-05-14 |
| 13F-HR | 2024-05-13 |
| 4 | 2024-03-25 |
| 4 | 2024-03-13 |
| 4 | 2024-02-29 |
| 13F-HR | 2024-02-09 |
| 13F-HR | 2023-11-13 |
| 4 | 2023-10-16 |
| 13F-HR | 2023-08-11 |
View Artal Group S.A.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.